短期nCPAP治疗对阻塞性睡眠呼吸暂停低通气综合征患者血清IL-6的影响
|
摘要
目的研究阻塞型睡眠呼吸暂停低通气综合征(obstructive sleep apneahyponea syndrome,OSAHS)患者血清白细胞介素6(IL-6)的变化,并观察短期经鼻持续气道正压通气(nasal continuous positive airway pressure,nCPAP)治疗对OSAHS患者血清IL-6的水平影响,并探讨nCPAP治疗对患者心血管系统的保护作用。
方法选择中、重度OSAHS患者26例(年龄:49±8岁,BMI:29.37±1.82kg/m~2)和正常对照组24例(年龄:48±10岁,BMI:28.51±1.99kg/m~2),测定并比较两组AHI及夜间最低SaO_2,平均最低SaO_2以及两组血清IL-6的水平,同时对OSAHS患者进行nCPAP治疗7天,测定治疗后的AHI及夜间最低SaO_2,平均最低SaO_2,血清IL-6水平,与治疗前相比较。采用SPSS13.0统计软件处理。同一指标的组间差异采用成组t检验,同一指标的前后比较采用配对t检验,两指标间采用线性相关分析。P＜0.05为差异有统计学意义。
结果OSAHS组呼吸暂停低通气指数(AHI apnea hypopnea index)、夜间最低SaO_2及平均SaO_2与正常对照组有明显差别(P＜0.01),且血清IL-6水平明显高于正常对照组(P＜0.01)。OSAHS组血清IL-6水平与睡眠呼吸暂停低通气指数(AHI)呈正相关(r=0.733,P＜0.01);与夜间最低SaO_2,平均最低SaO_2呈负相关(分别r=-0.793,P＜0.01;r=-0.759,P＜0.01)。
经过7天nCPAP治疗后,OSAHS患者自觉症状明显改善,AHI、夜间最低SaO_2及平均SaO_2也得到明显改善,血清IL-6水平较之治疗前明显下降(P＜0.01)。
结论血清IL-6水平与OSAHS密切相关,且其做为炎性因子可能预示着心血管并发症的危险性,而nCPAP治疗可能降低这个危险因素,对患者心血管系统起到保护作用。
Purpose:To explore the change of the serum interleukin-6 level in patients with obstructive sleep apnea hypopnea syndrom(OSAHS),and to study the effects of nasal continuous positive airway pressure on interleukin-6(IL-6)in serum of patients with obstructive sleep apnea hypopnea syndrome,and to explore the protection of nCPAP to the cardiovascular system of the patients of OSAHS.
Methods:Before and seven days after the therapy ofnCPAP,serum IL-6,the lowest and average SaO2 during nighttime and AHI was determined in the experimental group(n=26,AGE:49±8,BMI:29.37±1.82kg/m2)and compared with a normal control group(n=24,AGE:48±10,BMI:28.51±1.99kg/m2).
Results:The level of serum IL-6,the lowest and average SaO2 during nighttime and AHI have significant difference in 2 groups(P＜0.01),Before treatment,there were significant positive correlation between IL-6 and AHI in OSAHS patients (r=0.733,P＜0.01).significant negative correlation between IL-6 and the lowest and average SaO2 during nighttime(r=-0.793,P＜0.01;r=-0.759,P＜0.01); After nCPAP(7d),the serum level of IL-6 of OSAHS patients have reduced significantly(P＜0.01).
Conclusions:nCPAP can obviously decrease the level of serum IL-6 of OSAHS patients;therefore it may reduce the incidence of cardiovascular complication of OASHS patients,and protect their cardiovascular system.
方法选择中、重度OSAHS患者26例(年龄:49±8岁,BMI:29.37±1.82kg/m~2)和正常对照组24例(年龄:48±10岁,BMI:28.51±1.99kg/m~2),测定并比较两组AHI及夜间最低SaO_2,平均最低SaO_2以及两组血清IL-6的水平,同时对OSAHS患者进行nCPAP治疗7天,测定治疗后的AHI及夜间最低SaO_2,平均最低SaO_2,血清IL-6水平,与治疗前相比较。采用SPSS13.0统计软件处理。同一指标的组间差异采用成组t检验,同一指标的前后比较采用配对t检验,两指标间采用线性相关分析。P＜0.05为差异有统计学意义。
结果OSAHS组呼吸暂停低通气指数(AHI apnea hypopnea index)、夜间最低SaO_2及平均SaO_2与正常对照组有明显差别(P＜0.01),且血清IL-6水平明显高于正常对照组(P＜0.01)。OSAHS组血清IL-6水平与睡眠呼吸暂停低通气指数(AHI)呈正相关(r=0.733,P＜0.01);与夜间最低SaO_2,平均最低SaO_2呈负相关(分别r=-0.793,P＜0.01;r=-0.759,P＜0.01)。
经过7天nCPAP治疗后,OSAHS患者自觉症状明显改善,AHI、夜间最低SaO_2及平均SaO_2也得到明显改善,血清IL-6水平较之治疗前明显下降(P＜0.01)。
结论血清IL-6水平与OSAHS密切相关,且其做为炎性因子可能预示着心血管并发症的危险性,而nCPAP治疗可能降低这个危险因素,对患者心血管系统起到保护作用。
Purpose:To explore the change of the serum interleukin-6 level in patients with obstructive sleep apnea hypopnea syndrom(OSAHS),and to study the effects of nasal continuous positive airway pressure on interleukin-6(IL-6)in serum of patients with obstructive sleep apnea hypopnea syndrome,and to explore the protection of nCPAP to the cardiovascular system of the patients of OSAHS.
Methods:Before and seven days after the therapy ofnCPAP,serum IL-6,the lowest and average SaO2 during nighttime and AHI was determined in the experimental group(n=26,AGE:49±8,BMI:29.37±1.82kg/m2)and compared with a normal control group(n=24,AGE:48±10,BMI:28.51±1.99kg/m2).
Results:The level of serum IL-6,the lowest and average SaO2 during nighttime and AHI have significant difference in 2 groups(P＜0.01),Before treatment,there were significant positive correlation between IL-6 and AHI in OSAHS patients (r=0.733,P＜0.01).significant negative correlation between IL-6 and the lowest and average SaO2 during nighttime(r=-0.793,P＜0.01;r=-0.759,P＜0.01); After nCPAP(7d),the serum level of IL-6 of OSAHS patients have reduced significantly(P＜0.01).
Conclusions:nCPAP can obviously decrease the level of serum IL-6 of OSAHS patients;therefore it may reduce the incidence of cardiovascular complication of OASHS patients,and protect their cardiovascular system.
引文
[1] Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular diseasexross-sectional results of the sleep heart health study[J]. Am J Respir Crit Care Med, 2001,163(1):19-25.
[2] Young T, Palta M, Dempsey J, et al. The occurence of sleep disordered breathing among middleaged adults [J]. N Engl J Med, 1993, 328 (11): 1230-1234.
[3] Alberti A, Sarchielli P, Gallinella E, et al. Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study[J]. J Sleep Res, 2003, 12(4):305-311.
[4] Patarca R, Klimas NG, Lutendorf S, et al. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression [J]. Clin Infect Dis, 1994, 18[Suppl 1]: S147-S153.
[5] Kasasbeh E, Chi DS, Krishnaswamy G. Inflammatory aspects of sleep apnea and their cardiovascular consequences[J]. South Med J, 2006, 99(9): 58—67.
[6] Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome[J]. Chest, 2004, 126(3):1473-1479.
[7] Vgontzas AN, Papanicolaou DA, Bixler EO. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity[J]. J Clin Endocrinol Metab, 1997, 82(5): 1313-1316.
[8] Entzian P, Linnemann K, Schlaak M, et al.Obstructive sleep apnea and circadian rhythms of hormones and cytokines[J]. Am J Respir Crit Care Med, 1996, 153(3): 1080-1086.
[9] Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway presure[J]. Circulation, 2003, 107(8): 1129-1134.
[10]Gwedlenberger M, Hulsmarm M, Berger R, et al. Interleuldn-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure[J].Heart Lung Transplant, 2004, 23(7):839-844.
[11]Matsumori A, Shioi T, Yamada T, et al. A new inotropic agent, in hibits cytokine production by stimulated human blood from patients with heart failure. Circulation, 1994, 89(3): 955-958.
[12]Katanka T, Honda Y, Bonneau HN, et al. New catheter-based technology. For the treatment of restenosis[J]. Interv Cardiol, 2002, 15(5): 371-379.
[13]Rockson SG, Lorenz DP, Cheong WF, et al. Photoangloplasty: An emerging clinical cardiovascular role for photodynamie therapy[J]. Circulation. 2000, 102(5): 591-596.
[14]Hogye M, Mandi Y, Csanady M, et al. Comparison of circulating levels of interleuldn-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and iuidiopathic dilated cardiomyopathy[J].Am J Cardiol, 2004, 94(2): 249-251.
[15]Cugno M, Mari D, Memni P, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation[J]. Br J maermatol. 2004, 126(1): 85-92.
[16]Valgimigli M, Medi E, Malagutti P, et al. Sydroxyl generation, levels of tumor necrosis factor-alpha. and progression to heart failure after acute myocardial infarction[J]. Am Call Cardiol, 2004, 43(11): 2000-2005.
[17]FiSman MP, Buonaecorsi GA, Mareld R, et al. Reduction in the response to coronary and iliac artery injury with photodynamic therapy using 5-aminolaevulinic acid[J]. Cardiovasc Res, 2000, 45(2): 478-485.
[18]Olivier JP, Pocholle JP, Ricordell, et al. Experimental coronary angioplasty using hematopornphyrin coloration simultaneously with a pulsed laser beam[J]. Ann J Cardiol Angeiol, 1986, 35(2): 81-85.
[19]Hsu HY, Wang PY, Chen YT, et al. Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atotvastatin treatment in normolcholestemlemie patients[J]. Chin Med Assoc, 2005, 68(2): 53-58.
[20]Kyrzopulos S, Adamopoulos S, Parissis JT, et al. Levoslmondan reduces plasma -type natrittretie peptide and interleukin 6 and improves central hemodynamics in seven heart failure patients[J]. Int J Cardiol, 2005, 99(3): 409-413.
[21]Janpern SP, Gayanl G, Van den BA, et al. interleukin 6 in myocardial failure and skelet maple atrophy in rats[J]. Circulation, 2005, 111(8):996-1005.
[22]Lappi P, Licata A, italuszezak C, et al. Analysis of TCR beta repertoire and cytokine gone expression in patients with idiopathic dilated cardiomyapathy[J].Autolmmun,2001,16(1):3-13.
[23]Tone-Amioae G.Immune activation in chronic heart failure[J].Cardi,2005,11(2):4-7.
[24]Alter P,Hhen J,RitterM,et al.Usefulness of cytokines interleukin-6 and interleukin-2R concentrations in diagnosing active infective endocarditis involving native valves[J].Am J Cardiol,2002,89(12):1400-1404.
[25]Raymond RJ,Dehmer GJ,Gaeoharides TC,et al.Elevated interleukin-6 levels in patients with asymptomatie left ventrictdar dysfunction[J].An Heart J,2001,141:435-438.
[26]Merlini PA,Cuba M,Rossi ML,et al.Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction[J].Am J Cardiol,2004,93(7):822-825.
[27]Takahasi H,Fukunishi M,lbaraki Y,et al.Comparison of echocardiographic and morphological findings in patients with left atrial myxoma[J].Rinsho Byori.2003,51(3):274-277.
[28]Plez G,Eschert H,Ercen M.et al.The interleukin-6/interleukin-6 receptor system is activated in donor hearts[J].Am Coll Cardiol,2002,39:1508-1512.
[29]Vincent GM,Mackie RW,Onilane E,et al.In vivo photosensitizer,enhanced laser angioplasty in atherosclerotic Yucatan miniswine[J].Clin Laser Med Surg,1990,8(3):59-61.
[30]刘巍.白介素-6与心血管疾病[J].国际免疫学杂志,2006,29(1),37-40.
[31]Resfa O,Foschino-Barbaro MP,Talamo S,et al.Hyrercapnia in obstructive Sleep apnoea syndrome[J].Neth J Med,2000,56(6):215-222.
[32]Phillips BG,Narkiewiez K,Pesek CA,et al.Efects of obstructive sleep apnea on endothdin-1 and blood pressure[J].Hypertert8,1999,17(1).61-66.
[33]Dandona P,Ads A.A rational approach to pathogenesis and treatment of type 2diabetes mellitus,insulin resistance,inflammation,and atherosderosis[J].Am J Cardiol,2002,90(5):27-33.
[34]Kokturk O,Ciftci TU,Mollareep E,et al.Serum homocysteine levels and cardiovascular morbidityin obstructive sleep apnoea syndrome[J].Respit Med,2005,100(3):536-541.
[35]Kato M,Roberts Thomson P,Phillips BG,et al.Impairment of endothelium dependent vasedihtion of resistance vessels in patients with obstructive sleep apnea[J].Circulation,2000,102(21):2607-2610.
[36]Offen D,Ziv I,Gorodins S,et al.Dopamine-induced programmed cell death in mouse thymocytes[J].Biochim Biophys Acta,1995,1268(2):171-176.
[37]许国根,陈雯,张万光,全身炎症反应综合征患者致炎因子与抗炎因子的变化及相关性研究[J].中国急救医学,2002,22(6):320-321.
[38]Yan W,Suominen J,Toppari J,et al.Stem cell factor protects germ cells from apoptosis in vitro[J].Cell Sci,2000,113(1):161-168.
[39]Spector A.Oxidative stress and disease[J].Ocul Phamacol Ther,2000,16(2):193-201.
[40]Reinhold P,Langenberg A,Becher G,et al.Breath condensate a medium obtained by a noninvaIsive method for the detection of inflammation mediators of the lung[J],Berl Munch Fierarztl Wochenschr,1999,1 12(6-7):254-259.
[41]Carpagnanoc GE,K harltonov SA,Resta O,et al.Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients[J].Chest,2002,122(4):1162-1167.
[42]Ridker PM,Rifai N,Rose I,et al.Comparison of C-reactive protein and low-density lipopmteln cholesterol levels in the predlctlon of first cardiovascular events[J].N Engl J Med,2002,347(1):1557-1565.
[43]Tamakoshi I,Yatsuya H,Kondo T,et al.The metabolic syndrome is associated with elevated reculating C-reactive protein in healthy reference range,a systemic low-grade inflammatory state[J].Int J Obes Relat Meteb Disord,2003,27(4):443-449.
[44]Barzilay JI,Abraham L,Heckbert SR,et al.relation of markers of inflammation to the development of glucose disorders in the elderly:the cardiovascular Health Study[J].Diabetes 2001,50(2):2384-2389.
[45]Naveed S,Olga S,Ian F,et al.Elevated Alanine Aminotrans,ferase Predicts New-Onset Type Diabetes Independently of Classical Risk Factors,Metabolic Syndrome,and C-Reactive Protein in the West of Scotland Coronary Prevention Study[J].Diabetes,2004,53(7):2855-2860.
[46]Devaraj G,Kaditis,Emmanouel I,et al.Morning levels of C-reactive protein in children with obstructive sleep disordered breathing[J].Am J Respir Crit Care Med,2005,171(8):282-286.
[47]Blann V,Lipt JT.Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-athemsclemsis drugs[J].Circulation,2001,103(10):2531-2534.
[48]Hauner H.The Hew concept of adipose tissue function[J].Physiology Behavior 2004,83(1):653-658.
[49]Mohamed-Ali V,Goodriek S,Rawesh A,et al.Subcutaneous adipose tissue releases interleukin-6,but not tumor necrosis factor-a,in vivo[J].Clin Endocrinol Metab,1997,82(12):4196-4200.
[50]Susan KF,Dove AB,Andrew SG.Omental and subcutaneous adipose tissue of obese subjects relase interleukin-6:depot difference and regulation by glucocorticoid[J].Clin Endocrinol Metab,1998,83(3):847-850.
[51]Alexandros NV,Manolis Z,Edward OB,et al.Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 therapeutic implication[J].Clin Endocrinol Metab,2003,85(5):2087-2093.
[52]Visser K,Pernille K,Sonya M,et al.IL-6 gene expression in human adipose tissue in response to exercise-effect of carbohydrate ingestion[J].Physiol,2003,550(3):927-931.
[53]Peker Y,Kraiczi H,Hedner J,et al.An independent association between obstructive sleep apnea and coronary artery disease[J].Eur Respir J,1999,14:179-184.
[54]Kopp HP,Kopp CW,Festa A,et al.Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients[J].Arterioscler Thromb Vasc Biol,2003,23(6):1041-1047.
[55]姜辉,俞森洋.影响慢性阻塞性肺疾病无创通气治疗效果的因素[J].中国呼吸与危重监护杂志,2005,4(1):73-78.
[56]Massle CA,Hart RW,Peralez K,et al.Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure[J].Chest,1999,116(6):1140-1148.
[57]Teschler H,Farhat AA,Exnsr V,et al.Autoset nasal CPAP Ptitration:constancy of pressure,compliance and effectiveness at 8 month follow-up[J].Eur Respir J,1997,10(9):2073-2078.
[1]Young T,Palta M,Dempsey J,et al.The occurence of sleep disordered breathing among middleaged adults[J].N Engl J Med,1993,328(11):1230
[2]Chaban R,Cole P,Hofstein V.Site of upper airway obstruction inpatients with obstructive sleep apnea[J].Laryngoscope,1988,98(3):641
[3]Peppard PE,Young T,Palta M,et al.Prospective study of the association between sleep-disordered breathing and hypertension[J].N Engl J Med,2002,342(2):1378
[4]Yakki HK,Concato J,Kernan WN,et al.Obstructive sleep apnea as a risk factor for stroke and death[J].N Engl J Med,2005,353(3):2034
[5]McArdle N,Dervereux G,Heidamejad H,et al.Long-term use of CPAP therapy for obstructive sleep apnea/hypopnea syndrome[J].Am J Resoir Crit Care Med,1999,159(4):1108
[6]Bloch KE,Senn O,Iseli A.Oral appliances for treatment of snoring and obstructive sleep apnea in surgery for sleep apnea[J].The Hague,2003,1(7):559
[7]Hoekema A,Frant K,Zbestal A.Efficacy of oral appliances in the treatment of obstructive sleep apnea-hypopnea[J].Crit Rev Oral Biol Med,2004,4(3):137
[8]Gotsopoulos H,Chen C,Qian J,et al.Oral appliance therapy improves symptoms in obstructive sleep apnea: arandomized, controlled trial [J]. Am J Respir Crit Care Med, 2002, 166 (4): 743
[9] Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized controlled trial [J]. Sleep, 2004, 27 (3):934
[10] Barnes M, McEvoy RD, Banks S, et al. Efficacy of positive airway pressure and oral appliancein mild to moderate obstructive sleep apnea [J]. Am J RespirCrit Care Med, 2004, 170(8): 656
[11]Henke KG, Frantz DE, Kuna ST. An oral elastic mandibular advancement device for obstructive sleep apnea [J]. Am J Respir Crit Care Med, 2000,161 (5): 420
[12]Fritsch K, Iseli A, Russi EW, et al. Side effects of mandibular advancement devices for sleep apnea treatment [J]. Am J Respir Crit Care Med, 2001, 164 (3): 813
[13]Miki H, Hida W, Shindoh C, et al. Effects of electrical stimulation of the genioglossus on upper airway resistance in anesthetized dogs[J]. Am Rev Respir Di, 1989, 140(5): 1279
[14]Hida W,Okabe S,Miki H,et al. Effect of submental stimulation for patients with obstructive sleep apnoea[J]. Thorax, 1994,49(2):446
[15] Schwartz AR, Bennett ML, Smith PL, et al.Therape utie electrical stimulation of the hypoglossal nerve in obstructive sleep apnea [J]. Arch Otolaryngol Head Neck Surg, 2001, 127(9): 1216
[16]Dayyat E, Maarafeya MM, Capdevila OS, et al. Nocturnal body position in sleeping children with and without obstructive sleep apnea [J]. Pediatr Pulmonol, 2007, 125 (1): 98
[17]Dekok HJ. Case report: the medical treatment of obstructive sleep apnoea syndrome with Selenium [J]. Med Hypotheses,2005, 65 (4): 817
[18]Brouillette ET, Manoukian JJ, DuchaFme M, et al.Eficacy offluticasone nasat spray for pediatric obstructive sleep apnea [J]. Pediatr, 2001, 138(5): 838
[19]Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery [J]. N Engl J Med 2004, 351 (2): 2683
[20]Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and eta-analysis [J]. JAMA, 2004, 292 (9): 1724
[21] Stewart MG, Glaze DG, Friedman EM, et al. Quality of life and sleep study findings after adenotonsillectomy in children with obstructive sleep apnea [J].Arch Otolaryngol Head Neck Surg, 2005, 131 (8): 308
[22]Li KK, Powell NB, Riley RW, et al.Radiofrequency volumetric tissue reduction for treatment of turbinate hypertrophy.a pilot stuay [J]. Otolaryngol Head Neck Surg, 1998, 119(1): 569
[23]Utley DS, Goode RL, Hakim I. Radio frequeney energy tissue ablation for the treatment of nasal obstruction secondary to turbinate hypertrophy [J]. Laryngoscope, 2003,109(4): 683
[24] Sieskiewicz A, Olszewska E, Poplawska B, et al. Assessment of the effectiveness of uvulopalatopharyngoplasty (UPPP) in the treatment of mild and moderate OSA patients preliminarily selected for the procedure by simple clinical examination[J]. Otolaryngol Pol, 2006, 60 (3): 363
[25]Kamami YV. Outpatient treatment of sleep apnea syndrome with CO2 laser: laser-assisted UPPP[J]. Otolaryngol, 1994, 23 (1): 395
[26] Thomas AJ, Chavoya M, Terris DJ. Preliminary findings from a prospective, randomized trial of two tongue-base surgeries for sleep-disordered breathing[J]. Otolaryngol Head Neck Surg, 2003, 129 (10): 539
[27] Den Herder C, van Tinteren H, de Vries N. Hyoidothyroidopexy as a surgical treatment for obstructive sleep apnoea syndrome[J]. Ned Tijdschr Geneeskd, 2006, 28 (4): 198
[28]Foltan R, Pretl M, Donev F, et al. Changing of facial skeleton for treatment of obstructive sleep apnoea syndrome[J]. Prague Med Rep, 2005, 106 (2): 149
[29] Riley RW, Powell NB, Guilleminault C. Obstructive sleep apnea syndrome: A review of 306 consecutively treated surgical patients[J]. Otoloaryngol Head Neck Surg, 1993, 108 (7): 117
[30][Bettega G, Pepin JL, Veale D, et al. Obstructive sleep apnea syndrome, fifty-one consecutive patientstreated by maxillofacial surgery [J]. Am J Respir Crit Care Med, 2000, 162 (9): 641
[31] Phillips B. Upper airway surgery does not have a major role in the treatment of sleep apnea[J]. Clin Sleep Med, 2005, 1 (1): 241
[32]Jenkinson C, Davias RJ,Mullins R,et al.Comparison of therapeutic and subtherapeutic nasal continuous positive airway presure for obstructive sleep apnoea: a randomized prospecdve paralleltrial [J]. Lan cet,1999, 353(4): 101
[33]Pepin J L,Leger P,Veale D.et al.Side effects of nasal continuous positive airway pressure in sleep apnea syndrome study of 193 patients in two French sleep centers[J].Chest,1995,107(5):375
[34]Peker Y,Hedner J,Norum J.et al.Increased incidence of oardiovas,cular disease in middle aged men with obstructive sleep apnea:a 7 year follow up[J].Am J Res pir Crit Care Med,2002,166(1):159
[35]肖毅.自动持续气道正压通气治疗阻塞性睡眠呼吸暂停低通气综合征的应用[J].国外医学.呼吸系统分册,2003,23(5):248
[2] Young T, Palta M, Dempsey J, et al. The occurence of sleep disordered breathing among middleaged adults [J]. N Engl J Med, 1993, 328 (11): 1230-1234.
[3] Alberti A, Sarchielli P, Gallinella E, et al. Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study[J]. J Sleep Res, 2003, 12(4):305-311.
[4] Patarca R, Klimas NG, Lutendorf S, et al. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression [J]. Clin Infect Dis, 1994, 18[Suppl 1]: S147-S153.
[5] Kasasbeh E, Chi DS, Krishnaswamy G. Inflammatory aspects of sleep apnea and their cardiovascular consequences[J]. South Med J, 2006, 99(9): 58—67.
[6] Minoguchi K, Tazaki T, Yokoe T, et al. Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome[J]. Chest, 2004, 126(3):1473-1479.
[7] Vgontzas AN, Papanicolaou DA, Bixler EO. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep disturbance and obesity[J]. J Clin Endocrinol Metab, 1997, 82(5): 1313-1316.
[8] Entzian P, Linnemann K, Schlaak M, et al.Obstructive sleep apnea and circadian rhythms of hormones and cytokines[J]. Am J Respir Crit Care Med, 1996, 153(3): 1080-1086.
[9] Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway presure[J]. Circulation, 2003, 107(8): 1129-1134.
[10]Gwedlenberger M, Hulsmarm M, Berger R, et al. Interleuldn-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure[J].Heart Lung Transplant, 2004, 23(7):839-844.
[11]Matsumori A, Shioi T, Yamada T, et al. A new inotropic agent, in hibits cytokine production by stimulated human blood from patients with heart failure. Circulation, 1994, 89(3): 955-958.
[12]Katanka T, Honda Y, Bonneau HN, et al. New catheter-based technology. For the treatment of restenosis[J]. Interv Cardiol, 2002, 15(5): 371-379.
[13]Rockson SG, Lorenz DP, Cheong WF, et al. Photoangloplasty: An emerging clinical cardiovascular role for photodynamie therapy[J]. Circulation. 2000, 102(5): 591-596.
[14]Hogye M, Mandi Y, Csanady M, et al. Comparison of circulating levels of interleuldn-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and iuidiopathic dilated cardiomyopathy[J].Am J Cardiol, 2004, 94(2): 249-251.
[15]Cugno M, Mari D, Memni P, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation[J]. Br J maermatol. 2004, 126(1): 85-92.
[16]Valgimigli M, Medi E, Malagutti P, et al. Sydroxyl generation, levels of tumor necrosis factor-alpha. and progression to heart failure after acute myocardial infarction[J]. Am Call Cardiol, 2004, 43(11): 2000-2005.
[17]FiSman MP, Buonaecorsi GA, Mareld R, et al. Reduction in the response to coronary and iliac artery injury with photodynamic therapy using 5-aminolaevulinic acid[J]. Cardiovasc Res, 2000, 45(2): 478-485.
[18]Olivier JP, Pocholle JP, Ricordell, et al. Experimental coronary angioplasty using hematopornphyrin coloration simultaneously with a pulsed laser beam[J]. Ann J Cardiol Angeiol, 1986, 35(2): 81-85.
[19]Hsu HY, Wang PY, Chen YT, et al. Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atotvastatin treatment in normolcholestemlemie patients[J]. Chin Med Assoc, 2005, 68(2): 53-58.
[20]Kyrzopulos S, Adamopoulos S, Parissis JT, et al. Levoslmondan reduces plasma -type natrittretie peptide and interleukin 6 and improves central hemodynamics in seven heart failure patients[J]. Int J Cardiol, 2005, 99(3): 409-413.
[21]Janpern SP, Gayanl G, Van den BA, et al. interleukin 6 in myocardial failure and skelet maple atrophy in rats[J]. Circulation, 2005, 111(8):996-1005.
[22]Lappi P, Licata A, italuszezak C, et al. Analysis of TCR beta repertoire and cytokine gone expression in patients with idiopathic dilated cardiomyapathy[J].Autolmmun,2001,16(1):3-13.
[23]Tone-Amioae G.Immune activation in chronic heart failure[J].Cardi,2005,11(2):4-7.
[24]Alter P,Hhen J,RitterM,et al.Usefulness of cytokines interleukin-6 and interleukin-2R concentrations in diagnosing active infective endocarditis involving native valves[J].Am J Cardiol,2002,89(12):1400-1404.
[25]Raymond RJ,Dehmer GJ,Gaeoharides TC,et al.Elevated interleukin-6 levels in patients with asymptomatie left ventrictdar dysfunction[J].An Heart J,2001,141:435-438.
[26]Merlini PA,Cuba M,Rossi ML,et al.Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction[J].Am J Cardiol,2004,93(7):822-825.
[27]Takahasi H,Fukunishi M,lbaraki Y,et al.Comparison of echocardiographic and morphological findings in patients with left atrial myxoma[J].Rinsho Byori.2003,51(3):274-277.
[28]Plez G,Eschert H,Ercen M.et al.The interleukin-6/interleukin-6 receptor system is activated in donor hearts[J].Am Coll Cardiol,2002,39:1508-1512.
[29]Vincent GM,Mackie RW,Onilane E,et al.In vivo photosensitizer,enhanced laser angioplasty in atherosclerotic Yucatan miniswine[J].Clin Laser Med Surg,1990,8(3):59-61.
[30]刘巍.白介素-6与心血管疾病[J].国际免疫学杂志,2006,29(1),37-40.
[31]Resfa O,Foschino-Barbaro MP,Talamo S,et al.Hyrercapnia in obstructive Sleep apnoea syndrome[J].Neth J Med,2000,56(6):215-222.
[32]Phillips BG,Narkiewiez K,Pesek CA,et al.Efects of obstructive sleep apnea on endothdin-1 and blood pressure[J].Hypertert8,1999,17(1).61-66.
[33]Dandona P,Ads A.A rational approach to pathogenesis and treatment of type 2diabetes mellitus,insulin resistance,inflammation,and atherosderosis[J].Am J Cardiol,2002,90(5):27-33.
[34]Kokturk O,Ciftci TU,Mollareep E,et al.Serum homocysteine levels and cardiovascular morbidityin obstructive sleep apnoea syndrome[J].Respit Med,2005,100(3):536-541.
[35]Kato M,Roberts Thomson P,Phillips BG,et al.Impairment of endothelium dependent vasedihtion of resistance vessels in patients with obstructive sleep apnea[J].Circulation,2000,102(21):2607-2610.
[36]Offen D,Ziv I,Gorodins S,et al.Dopamine-induced programmed cell death in mouse thymocytes[J].Biochim Biophys Acta,1995,1268(2):171-176.
[37]许国根,陈雯,张万光,全身炎症反应综合征患者致炎因子与抗炎因子的变化及相关性研究[J].中国急救医学,2002,22(6):320-321.
[38]Yan W,Suominen J,Toppari J,et al.Stem cell factor protects germ cells from apoptosis in vitro[J].Cell Sci,2000,113(1):161-168.
[39]Spector A.Oxidative stress and disease[J].Ocul Phamacol Ther,2000,16(2):193-201.
[40]Reinhold P,Langenberg A,Becher G,et al.Breath condensate a medium obtained by a noninvaIsive method for the detection of inflammation mediators of the lung[J],Berl Munch Fierarztl Wochenschr,1999,1 12(6-7):254-259.
[41]Carpagnanoc GE,K harltonov SA,Resta O,et al.Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients[J].Chest,2002,122(4):1162-1167.
[42]Ridker PM,Rifai N,Rose I,et al.Comparison of C-reactive protein and low-density lipopmteln cholesterol levels in the predlctlon of first cardiovascular events[J].N Engl J Med,2002,347(1):1557-1565.
[43]Tamakoshi I,Yatsuya H,Kondo T,et al.The metabolic syndrome is associated with elevated reculating C-reactive protein in healthy reference range,a systemic low-grade inflammatory state[J].Int J Obes Relat Meteb Disord,2003,27(4):443-449.
[44]Barzilay JI,Abraham L,Heckbert SR,et al.relation of markers of inflammation to the development of glucose disorders in the elderly:the cardiovascular Health Study[J].Diabetes 2001,50(2):2384-2389.
[45]Naveed S,Olga S,Ian F,et al.Elevated Alanine Aminotrans,ferase Predicts New-Onset Type Diabetes Independently of Classical Risk Factors,Metabolic Syndrome,and C-Reactive Protein in the West of Scotland Coronary Prevention Study[J].Diabetes,2004,53(7):2855-2860.
[46]Devaraj G,Kaditis,Emmanouel I,et al.Morning levels of C-reactive protein in children with obstructive sleep disordered breathing[J].Am J Respir Crit Care Med,2005,171(8):282-286.
[47]Blann V,Lipt JT.Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-athemsclemsis drugs[J].Circulation,2001,103(10):2531-2534.
[48]Hauner H.The Hew concept of adipose tissue function[J].Physiology Behavior 2004,83(1):653-658.
[49]Mohamed-Ali V,Goodriek S,Rawesh A,et al.Subcutaneous adipose tissue releases interleukin-6,but not tumor necrosis factor-a,in vivo[J].Clin Endocrinol Metab,1997,82(12):4196-4200.
[50]Susan KF,Dove AB,Andrew SG.Omental and subcutaneous adipose tissue of obese subjects relase interleukin-6:depot difference and regulation by glucocorticoid[J].Clin Endocrinol Metab,1998,83(3):847-850.
[51]Alexandros NV,Manolis Z,Edward OB,et al.Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 therapeutic implication[J].Clin Endocrinol Metab,2003,85(5):2087-2093.
[52]Visser K,Pernille K,Sonya M,et al.IL-6 gene expression in human adipose tissue in response to exercise-effect of carbohydrate ingestion[J].Physiol,2003,550(3):927-931.
[53]Peker Y,Kraiczi H,Hedner J,et al.An independent association between obstructive sleep apnea and coronary artery disease[J].Eur Respir J,1999,14:179-184.
[54]Kopp HP,Kopp CW,Festa A,et al.Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients[J].Arterioscler Thromb Vasc Biol,2003,23(6):1041-1047.
[55]姜辉,俞森洋.影响慢性阻塞性肺疾病无创通气治疗效果的因素[J].中国呼吸与危重监护杂志,2005,4(1):73-78.
[56]Massle CA,Hart RW,Peralez K,et al.Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure[J].Chest,1999,116(6):1140-1148.
[57]Teschler H,Farhat AA,Exnsr V,et al.Autoset nasal CPAP Ptitration:constancy of pressure,compliance and effectiveness at 8 month follow-up[J].Eur Respir J,1997,10(9):2073-2078.
[1]Young T,Palta M,Dempsey J,et al.The occurence of sleep disordered breathing among middleaged adults[J].N Engl J Med,1993,328(11):1230
[2]Chaban R,Cole P,Hofstein V.Site of upper airway obstruction inpatients with obstructive sleep apnea[J].Laryngoscope,1988,98(3):641
[3]Peppard PE,Young T,Palta M,et al.Prospective study of the association between sleep-disordered breathing and hypertension[J].N Engl J Med,2002,342(2):1378
[4]Yakki HK,Concato J,Kernan WN,et al.Obstructive sleep apnea as a risk factor for stroke and death[J].N Engl J Med,2005,353(3):2034
[5]McArdle N,Dervereux G,Heidamejad H,et al.Long-term use of CPAP therapy for obstructive sleep apnea/hypopnea syndrome[J].Am J Resoir Crit Care Med,1999,159(4):1108
[6]Bloch KE,Senn O,Iseli A.Oral appliances for treatment of snoring and obstructive sleep apnea in surgery for sleep apnea[J].The Hague,2003,1(7):559
[7]Hoekema A,Frant K,Zbestal A.Efficacy of oral appliances in the treatment of obstructive sleep apnea-hypopnea[J].Crit Rev Oral Biol Med,2004,4(3):137
[8]Gotsopoulos H,Chen C,Qian J,et al.Oral appliance therapy improves symptoms in obstructive sleep apnea: arandomized, controlled trial [J]. Am J Respir Crit Care Med, 2002, 166 (4): 743
[9] Gotsopoulos H, Kelly JJ, Cistulli PA. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized controlled trial [J]. Sleep, 2004, 27 (3):934
[10] Barnes M, McEvoy RD, Banks S, et al. Efficacy of positive airway pressure and oral appliancein mild to moderate obstructive sleep apnea [J]. Am J RespirCrit Care Med, 2004, 170(8): 656
[11]Henke KG, Frantz DE, Kuna ST. An oral elastic mandibular advancement device for obstructive sleep apnea [J]. Am J Respir Crit Care Med, 2000,161 (5): 420
[12]Fritsch K, Iseli A, Russi EW, et al. Side effects of mandibular advancement devices for sleep apnea treatment [J]. Am J Respir Crit Care Med, 2001, 164 (3): 813
[13]Miki H, Hida W, Shindoh C, et al. Effects of electrical stimulation of the genioglossus on upper airway resistance in anesthetized dogs[J]. Am Rev Respir Di, 1989, 140(5): 1279
[14]Hida W,Okabe S,Miki H,et al. Effect of submental stimulation for patients with obstructive sleep apnoea[J]. Thorax, 1994,49(2):446
[15] Schwartz AR, Bennett ML, Smith PL, et al.Therape utie electrical stimulation of the hypoglossal nerve in obstructive sleep apnea [J]. Arch Otolaryngol Head Neck Surg, 2001, 127(9): 1216
[16]Dayyat E, Maarafeya MM, Capdevila OS, et al. Nocturnal body position in sleeping children with and without obstructive sleep apnea [J]. Pediatr Pulmonol, 2007, 125 (1): 98
[17]Dekok HJ. Case report: the medical treatment of obstructive sleep apnoea syndrome with Selenium [J]. Med Hypotheses,2005, 65 (4): 817
[18]Brouillette ET, Manoukian JJ, DuchaFme M, et al.Eficacy offluticasone nasat spray for pediatric obstructive sleep apnea [J]. Pediatr, 2001, 138(5): 838
[19]Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery [J]. N Engl J Med 2004, 351 (2): 2683
[20]Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and eta-analysis [J]. JAMA, 2004, 292 (9): 1724
[21] Stewart MG, Glaze DG, Friedman EM, et al. Quality of life and sleep study findings after adenotonsillectomy in children with obstructive sleep apnea [J].Arch Otolaryngol Head Neck Surg, 2005, 131 (8): 308
[22]Li KK, Powell NB, Riley RW, et al.Radiofrequency volumetric tissue reduction for treatment of turbinate hypertrophy.a pilot stuay [J]. Otolaryngol Head Neck Surg, 1998, 119(1): 569
[23]Utley DS, Goode RL, Hakim I. Radio frequeney energy tissue ablation for the treatment of nasal obstruction secondary to turbinate hypertrophy [J]. Laryngoscope, 2003,109(4): 683
[24] Sieskiewicz A, Olszewska E, Poplawska B, et al. Assessment of the effectiveness of uvulopalatopharyngoplasty (UPPP) in the treatment of mild and moderate OSA patients preliminarily selected for the procedure by simple clinical examination[J]. Otolaryngol Pol, 2006, 60 (3): 363
[25]Kamami YV. Outpatient treatment of sleep apnea syndrome with CO2 laser: laser-assisted UPPP[J]. Otolaryngol, 1994, 23 (1): 395
[26] Thomas AJ, Chavoya M, Terris DJ. Preliminary findings from a prospective, randomized trial of two tongue-base surgeries for sleep-disordered breathing[J]. Otolaryngol Head Neck Surg, 2003, 129 (10): 539
[27] Den Herder C, van Tinteren H, de Vries N. Hyoidothyroidopexy as a surgical treatment for obstructive sleep apnoea syndrome[J]. Ned Tijdschr Geneeskd, 2006, 28 (4): 198
[28]Foltan R, Pretl M, Donev F, et al. Changing of facial skeleton for treatment of obstructive sleep apnoea syndrome[J]. Prague Med Rep, 2005, 106 (2): 149
[29] Riley RW, Powell NB, Guilleminault C. Obstructive sleep apnea syndrome: A review of 306 consecutively treated surgical patients[J]. Otoloaryngol Head Neck Surg, 1993, 108 (7): 117
[30][Bettega G, Pepin JL, Veale D, et al. Obstructive sleep apnea syndrome, fifty-one consecutive patientstreated by maxillofacial surgery [J]. Am J Respir Crit Care Med, 2000, 162 (9): 641
[31] Phillips B. Upper airway surgery does not have a major role in the treatment of sleep apnea[J]. Clin Sleep Med, 2005, 1 (1): 241
[32]Jenkinson C, Davias RJ,Mullins R,et al.Comparison of therapeutic and subtherapeutic nasal continuous positive airway presure for obstructive sleep apnoea: a randomized prospecdve paralleltrial [J]. Lan cet,1999, 353(4): 101
[33]Pepin J L,Leger P,Veale D.et al.Side effects of nasal continuous positive airway pressure in sleep apnea syndrome study of 193 patients in two French sleep centers[J].Chest,1995,107(5):375
[34]Peker Y,Hedner J,Norum J.et al.Increased incidence of oardiovas,cular disease in middle aged men with obstructive sleep apnea:a 7 year follow up[J].Am J Res pir Crit Care Med,2002,166(1):159
[35]肖毅.自动持续气道正压通气治疗阻塞性睡眠呼吸暂停低通气综合征的应用[J].国外医学.呼吸系统分册,2003,23(5):248